Skip to main content

adavosertib

Generic: Adavosertib

adavosertib: 4 clinical trials tracked.

adavosertib evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about adavosertib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 2 study sponsors
Clinical Trials (4)

EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition

NCT03579316·Phase 2·ADMA
Active, not recruiting

Primary endpoint: Objective response rate

InterventionalRandomizedopen96 targetStarted 2018-12Completion 2026-122 sites · United StatesM.D. Anderson Cancer Center

A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) in Combination With MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

NCT02617277·Phase 1·AZN
Completed

Primary endpoint: The incidence of Dose Limiting Toxicities (DLTs)

Interventionalopen56 enrolledStarted 2015-12Completion 2026-023 sites · United StatesAstraZeneca

A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

NCT02513563·Phase 2·ADMA
Completed

Primary endpoint: Progression Free Survival (PFS)

Interventionalopen42 enrolledStarted 2015-10Completion 2023-112 sites · United StatesH. Lee Moffitt Cancer Center and Research Institute

Molecular Analysis for Therapy Choice (MATCH)

NCT02465060·Phase 2·ADMA
Active, not recruiting

Primary endpoint: Objective response rate (ORR)

Interventionalopen6,452 targetStarted 2015-08Completion 2026-1250 sites · United StatesNational Cancer Institute (NCI)